Non-Toxic Gel to Treat Vulvovaginal Candidiasis

Information

  • Research Project
  • 7051865
  • ApplicationId
    7051865
  • Core Project Number
    R43AI068375
  • Full Project Number
    1R43AI068375-01
  • Serial Number
    68375
  • FOA Number
  • Sub Project Id
  • Project Start Date
    5/1/2006 - 18 years ago
  • Project End Date
    4/30/2008 - 16 years ago
  • Program Officer Name
    DUNCAN, RORY A.
  • Budget Start Date
    5/1/2006 - 18 years ago
  • Budget End Date
    4/30/2008 - 16 years ago
  • Fiscal Year
    2006
  • Support Year
    1
  • Suffix
  • Award Notice Date
    4/25/2006 - 18 years ago

Non-Toxic Gel to Treat Vulvovaginal Candidiasis

[unreadable] DESCRIPTION (provided by applicant): The goal of this project is to develop a safe biocidal vaginal gel for treatment of vulvovaginal candidiasis (WC). WC is caused by one of several airborne species of the yeast Candida that are normal inhabitants of humans at several sites, including the vagina. C. albicans has been associated with causing WC in the past, but drug-resistant non-C. albicans spp. are increasingly being identified as the cause of WC. Many of: he non-C. albicans strains are resistant to normal levels of antifungal drugs. As a result, recurrent WC has become an increasingly common and chronic problem, with patients becoming refractory to treatment due to imitations in available therapy. Biomedical Development Corporation (BDC) is evaluating lova gel as a novel, safe, and effective microbicide. lova gel is a broad-spectrum biocide with activity against viruses, bacteria, and yeast, without nducing resistant mutants or allergenicity. The goal of this project is to develop lova vaginal gel as a treatment for vulvovaginal candidiasis. BDC will execute the following specific aims: Specific Aim 1: Formulate lova Gel Formulations for Use in Treating Vulvovaginal Candidiasis Specific Aim 2: Demonstrate Safety of lova Gel Formulations Specific Aim 3: Demonstrate Effectiveness of lova Gel Formulations in Killing Planktonic Candida spp. Specific Aim 4: Demonstrate that lova Gel is Effective in Eradicating a Persistent Candida albicans Vaginal Infection in Rats , Relevance to Public Health: Vaginitis is the most common gynecologic diagnosis in primary care globally, affecting an estimated 1 billion women each year. WC accounts for 30-45% of vaginitis, and approximately 75% of premenopausal women will have at least one episode of WC. Among premenopausal women, 70- 75% will have at least one episode of WC and half of all college women will, by age 25, have had one episode of WC diagnosed by a physician. Annual costs for treating WC in the U.S. are estimated at $1.8 billion. [unreadable] [unreadable]

IC Name
NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES
  • Activity
    R43
  • Administering IC
    AI
  • Application Type
    1
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
    110322
  • Sub Project Total Cost
  • ARRA Funded
  • CFDA Code
    856
  • Ed Inst. Type
  • Funding ICs
    NIAID:110322\
  • Funding Mechanism
  • Study Section
    ZRG1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    BIOMEDICAL DEVELOPMENT CORPORATION
  • Organization Department
  • Organization DUNS
  • Organization City
    SAN ANTONIO
  • Organization State
    TX
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    782163610
  • Organization District
    UNITED STATES